Urology Times
Spotlight
Urology Times JournalProstate CancerBladder CancerOAB and IncontinenceSUO Annual MeetingAround the Practice: January 2021 Virtual Tumor BoardAUA ConferenceBPHEvolving Treatment ApproachesPerspectives in mCRPCThe Latest in Testosterone Replacement Therapy
Opinion
BlogsResidents Lounge
Business
View MoreHealth ITHealth Law & PolicyMalpractice ConsultPersonal FinancePractice Management
News
Clinical
All ClinicalBenign ConditionsBladder CancerBPHChallenging AnatomyDrug TherapyFemale UrologyGenitourinary CancersKidney CancerKidney StonesMen's HealthPediatricsProstate CancerSexual DysfunctionUrologic Surgery
Media
Podcasts'Y'tubeK-CastUTv VideosAround the PracticeBPH VideosMedical World NewsReadout 360Viewpoints
Conferences
Publications
Urologists in Cancer CareUrology Times Journal
Events
Live EventsVirtual Events
CME/CE
Resources
Interactive ToolsJob BoardSponsored
Subscribe
eNewsletterPrint Subscription

  • Advertise
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do not sell my Personnal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Urology Times. All rights reserved.

Spotlight
  • Urology Times Journal
  • Prostate Cancer
  • Bladder Cancer
  • OAB and Incontinence
  • SUO Annual Meeting
  • Around the Practice: January 2021 Virtual Tumor Board
  • AUA Conference
  • BPH
  • Evolving Treatment Approaches
  • Perspectives in mCRPC
  • The Latest in Testosterone Replacement Therapy
Opinion
  • Blogs
  • Residents Lounge
BusinessSee All >
  • Health IT
  • Health Law & Policy
  • Malpractice Consult
  • Personal Finance
  • Practice Management
  • Advertise
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do not sell my Personnal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.

Dr. Stephen A. Boorjian on the next steps with nadofaragene firadenovec in NMIBC

February 23, 2021
Urology Times staff
Urology Times staff

Boorjian anticipates research with nadofaragene firadenovec in settings beyond BCG-unresponsive non-muscle invasive bladder cancer.

Stephen A. Boorjian, MD, professor of urology at Mayo Clinic, Rochester, MN, discusses the next steps with the antibody-drug conjugate (ADC) nadofaragene firadenovec in non-muscle invasive bladder cancer (NMIBC).

In a pivotal phase 3 trial of patients with BCG-unresponsive NMIBC, nadofaragene firadenovec achieved a complete response (CR) rate of 53.4% at 3 months in a subgroup of patients with carcinoma in situ with or without concomitant high-grade Ta or T1 disease. The 12-month CR rate was 24.3% and the median duration of CR was 9.69 months in these patients.

Boorjian says that if the ADC receives FDA approval, next steps include combination trials, as well as studying nadofaragene firadenovec in other disease states of NMIBC.

Related Content:

Bladder Cancer
Dr. Bishoy M. Faltas on the role of genomic testing in bladder cancer
Dr. Bishoy M. Faltas on the role of genomic testing in bladder cancer
Dr. Thomas Powles explains standard treatment for metastatic urothelial cancer
Dr. Thomas Powles explains standard treatment for metastatic urothelial cancer
Dr. Shaakir Hasan discusses disparities in bladder cancer diagnosis and treatment
Dr. Shaakir Hasan discusses disparities in bladder cancer diagnosis and treatment